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Abstract 
 
In this paper the chemical imaging technique by near infrared spectroscopy was 
applied for characterization of drug formulations in tablets of sildenafil citrate of 
different sources. This work is original and has never been published because it 
was used the sildenafil citrate, including in the commercial one called "Viagra". 
In the first stage of the study, a chemometric method based on multivariate 
curve resolution was properly chosen for the development of the distribution 
map of concentrations of the active ingredient in tablets. In the second step, the 
normalized histograms of images from active ingredient were classified by 
hierarchical cluster analysis. Finally it was possible to recognize the patterns of 
homogeneity of images in sildenafil citrate tablet. This concept can be used to 
improve the knowledge of industrial products and processes, as well as, for 
characterization of counterfeit drugs. 
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Introduction 
Patents are a form of legal protection of intellectual property that provide 
exclusive rights to make, use, import, sell and offer for sale the invention for up 
to 20 years. The economic logic of this protection mechanism is that the profits 
provided by the production license of a patented product guarantee the patent 
owner the reinvestment in research and development of new products1-4. Social 
factors, however, may eventually prevail over this economic development 
engine aspect, discussing the possibility of patent infringement. One of these 
factors is the great technological discrepancy in peripheral countries in relation 
to developed countries, and their low purchasing power to buy the next-
generation products manufactured by the major economic centers. 
Viagra® is the first drug approved to treat erectile dysfunction. Its 
mechanism is blocking the enzyme phosphodiesterase type 5 (PDE5), involved 
in the erection process. It has vasodilating properties and effects on blood 
pressure, and like nitrates, it works by the nitric oxide cyclic guanosine 
monophosphate pathway5,6. It is estimated that erectile dysfunction affects 
between 48 % and 52 % of men from 40 to 70 years. 
The sildenafil citrate (active ingredient of the Viagra®) was registered in 
the European Union in 1991 by Pfizer. Nowadays, due to the expiration of the 
patent in Brazil, at least ten different companies are marketing this product, but 
in cheaper way. Additionally, the counterfeiting of Viagra® tablets has become 
an important and dangerous problem for pharmaceutical market, where the 
Brazilian Federal Police has reported many seizures mainly in south region of 
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Brazil (state of Parana). In 2007-2010 periods, the Federal Police reported a 
great numbers of seizures (371) being the counterfeit tablets market related to 
erectile dysfunction treatment responsible by 80 % of the seizures. Therefore, to 
control the quality of new pharmaceutical formulations and distinguish between 
authentic and counterfeit tablets is necessary the development of powerful 
analytical tools. Although analytical methods such as chromatography7-10, 
voltammetry11-13 and colorimetric determination14 were reported in Viagra® 
tablets analysis, they are high time-consuming and require extensive sample 
preparation.  
Due to its advantages such as non-destructive analysis, speed, and less 
consumption of chemicals, the near infrared spectroscopy (NIR) has been 
accepted in various fields of pharmaceutical industry15,16. NIR has the potential 
to provide increased process and product understanding which goes well with 
the process analytical technology (PAT) initiative of the Food and Drug 
Administration (FDA)17.  
 Hyperspectral imaging shows a considerable promise for providing high-
quality spectral information on active principle distribution within pharmaceutical 
formulations. The robust reliable combination of chemical (molecular 
spectroscopy) and physical (digital imaging) features have been successfully 
applied to diverse fields such as remote sensing18,19, astronomy20,21, 
agriculture21,22, food23 and pharmaceuticals24-26. 
Quantitative analysis of pharmaceutical samples using Near Infrared-
Chemical Imaging (NIR-CI) has been performed in techniques as Partial Least 
Squares Regression (PLS) or PLS-Discriminant Analysis (PLS-DA)24,26,27.  
However, these techniques require a complete calibration set of samples with 
5 
 
the corresponding time consuming until the calibration model that is performed 
and adequately tested. Concerning the quantification purposes without needing 
a previous calibration model, Multivariate Curve Resolution - Alternating Least 
Squares (MCR-ALS) may be presented as a promising alternative by using 
second order advantage, i.e., analytes quantification in the presence of 
unknown interference. MCR-ALS is an algorithm that fits the requirements for 
image resolution28-31.This method decompose the unfolded hyperspectral data 
cube, the matrix X (xy × λ), into the product of two matrices, C (xy × K), 
containing the concentration profiles and ST (K × λ), containing the spectral 
profiles for each K component (Figure 1 and equation 1). In this case, xy is the 
spatial image dimensions and λ the number of spectral data points. 
 
X = CST + E                                                 (1) 
 
where E (xy × λ) corresponds to the experimental error matrix. 
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Figure 1. Scheme of MCR-ALS analysis application to the hyperspectral cube. 
 To initiate the iterative MCR-ALS procedure, an initial estimation is 
needed for the spectral profiles. Different methods are used for this purpose 
such as evolving factor analysis32-34, the determination of the purest variables35-
38 or by using pure spectra of the components39.  
This work aims to build a concentration distribution map of sildenafil 
citrate in tablets of different sources where the chemical composition of all 
excipients constituents is not truly known using the multivariate curve resolution 
approach. In addition, the profile of the concentration distribution maps for each 
tablet were assessed for obtaining recognition pattern of images by analyzing 
hierarchical classification of their histograms.  
  
Experimental section 
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In this work, tablets containing sildenafil citrate as active ingredient of six 
different formulations from different sources were studied. These formulations 
were named as A to F. The formulations from A to E were provided by Brazilian 
Federal Police and correspond to several trademarks of prohibited marketing. 
The F formulation was an authentic sample of Viagra® (Pfizer Ltda). For each 
formulation, it was performed an image acquisition of four tablets.    
The acquisition of images was obtained by NIR-CI technique using 
Spotlight 400N FT-NIR Imaging by PerkinElmer. The mapping measurements 
were performed four times per sample type, spatial resolution 25 µm, 16 scans 
and spectral range between 6500 and 4000 cm-1. The data array (80x80 pixels 
and 158 wavelengths) was obtained directly on surface of the tablet (after 
coating removal). The raw data were transformed to inverse logarithm of the 
reflectance values (pseudo-absorbance) and unfolded for further preprocessing 
by Multiplicative Scattering Correction (MSC). Since only the sildenafil citrate 
spectrum is known in advance, the tool choose for construction of the 
distribution maps was the MCR31 as a quantitative way. The ALS optimization 
was initialized by loadings of Principal Component Analysis (PCA) using mean-
centered data. Constraints as external spectral knowledge of the active 
ingredient as well as non-negativity and closure for concentration were used as 
a way to minimize rotation ambiguity. Thus, the standard spectrum of sildenafil 
citrate was compared among all loadings per sample and substituted by its 
most similar loading profile and a new optimization process using ALS was 
performed. In this direction, semi-quantitative information can be obtained for 
active ingredient by recovering spectral information after optimization stage. 
The distribution maps (images) were converted to histograms of pixel 
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concentration. Those histograms were normalized (mean concentration = 1) 
and classified by non-supervised Hierarchical Cluster Analysis (HCA).  
Data analysis was performed in Matlab version 7.8 using routines 
developed in the laboratory and the MCR Toolbox provided by Romà Tauler31.  
 
Results and discussion 
 
The first step in the development of the MCR-ALS modeling was the 
initialization of the model by using the loadings obtained by principal component 
analysis. The use of loadings for initialization of the MCR-ALS can be 
considered problematic for optimization of the C matrix (concentration), since 
the rotation ambiguity is present in this situation. In other words, the quantitative 
approach used in multivariate resolution, Equation 1, would be confounded by 
qualitative information of T-matrix (scores) and P-matrix (loadings) obtained by 
PCA analysis, Equation 2.  
X = TPT + E                                                 (2) 
 
In this case, the C matrix would bring T matrix qualitative information 
because of the initializations by loadings. In this sense, the use of the purest S 
matrix and constraints are frequently a way for minimization of the ambiguities 
and recovery quantitative information. However, the purest spectra may present 
high condition number in relatively homogeneous images (i.e. high similarity 
among all spectral information) while loadings are always orthogonal with 
condition number equal to one. In MCR-ALS, E matrix (errors) can be seen as a 
lack of fit of the product of C-matrix (concentrations) and S matrix (pure spectra) 
for recovery the X matrix. For good results, it is desirable decreasing the 
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sensitivity of the E matrix. In this direction, a lower condition number of S matrix 
contributes to highest robustness for C matrix. 
Due to use of loadings combined with sildenafil citrate pure spectrum for 
initialization of MCR-ALS, a high orthogonally was reached. On the other hand, 
the results of MRC-ALS optimization, Figure 2, show excellent recoveries for 
the active ingredient spectra for all drug formulations samples.  
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Figure 2. Overlap of the spectra of sildenafil citrate: standard and optimized by 
MCR-ALS for the drug formulations A to F.  
In Figure 2, the dotted spectra were obtained directly from a standard of 
sildenafil citrate, while the line spectra were obtained by MCR-ALS. Note that 
the information recovered from optimization process in MCR is highly correlated 
with the known spectrum of the active ingredient standard, reaching selectivity 
for quantitative approach. Moreover, loadings assurance a lower similarity 
among all excipients and sildenafil citrate profiles, which help increase the 
sensitivity of the results. 
This procedure is especially interesting for analysis where the components 
are not totaly known, but only part of the information is available. The lack of fit 
lower than 1% between the MCR-ALS resolution results and the original X 
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matrices added to good recovery of the sildenafil citrate spectrum assurance 
reliable images. The calculation of the lack of fit was performed by using the 
Equation 3: 
 
where  is an element of the experimental matrix X and  the element of the 
MCR-ALS reproduced matrix X*.  
In Figure 3, concentration maps of four different tablets for each source of 
the drug formulation (A to F) are showed. Note that on the drug A, there are a 
lot of big heterogeneous regions (i.e. excipient has big particle size) also 
observed on tablets through to optical microscopic view. In second line B a 
slightly different profile arises, smaller and denser point of active may be seen. 
In next two samples, respectively C and D, more homogeneous images are 
brought. Those drugs have very similar characteristics; maybe by represent the 
same brand, but different packaging, batch and seizure. Likewise A, the drug 
formulation E is recognized by low homogeneity that divides yours pixels at 
nearly absence or presence of the sildenafil information. The drug formulation 
F, the original drug formulation, presents a very homogeneous profile of 
concentration. Moreover, similar pattern of distributions among image replicates 
is possible to observe in this figure.  
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Figure 3. Distribution maps of concentration to six different drugs (A-F) 
obtained by MCR-ALS.  
 
The images above can be translated into histograms of frequency 
distribution of concentrations. This type of result analysis removes the spatial 
components xy of the acquired information, but retains the ability to study the 
distribution profile, i.e., the homogeneity of the active ingredient information. 
In Figure 4, histograms were normalized in order that the mean 
concentration is equal to one. Thus, it becomes possible to analyze profile of 
histograms independently of its mass fraction on the tablets surface.  
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Figure 4. Histogram of the images centered at unit for the drug formulations A 
to F. 
 
The histogram is a graphical technique for showing both the skewness 
and kurtosis of the data set. In this case, it is represented by the frequency 
distribution of concentrations. Kurtosis is a measure of whether the data are 
peaked or flat relative to a normal distribution. Negative kurtosis would indicate 
a flat distribution, which is said to be platykurtic. Positive kurtosis would indicate 
a peaked distribution, which is said to be leptokurtic. Finally, the normal 
distribution has zero kurtosis, and it is said to be mesokurtic. In Figure 4, it is 
possible to classify the kurtosis from the concentration distribution of D and F 
drugs in mesokurtic, because among the six drugs analyzed they have a more 
homogeneous concentration distribution on the drug surface. For A, B and E 
Tablet 1                     Tablet 2                                Tablet 3                  Tablet 4             
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drugs the kurtosis can be classified as platykurtic, because they are less 
homogeneous. For C drugs the kurtosis can be classified as leptokurtic. 
Skewness is a measure of the distribution symmetry, or more precisely, 
the lack of symmetry. From observation of the Figure 4, it can be inferred that in 
A and E formulations the sildenafil citrate concentration distribution on the 
surface is less symmetrical due to the particle size heterogeneity in those 
formulations. By the other hand, B, C, D and F formulations have  more 
symmetrical distribution among the formulations studied, since the size of the 
particles are more homogeneous. Therefore, it can be concluded that by 
kurtosis and skewness histogram classification it is possible to study drug 
formulation homogeneity. Also they can be used as an indicative to characterize 
the formulations.  
In order to provide a pattern recognition of the distribution of sildenafil 
citrate concentrations in tablets, it was used an established chemometric 
method called HCA. It is based on the multivariate distances among the 
samples by using an agglomerative procedure. The objective has been to 
provide a classification non-supervisioned of the different kind of drugs by 
similarity of distribution of the active. Thus, to show a way to recognition of 
images and its variability is an important parameter to study within and between 
samples. The dendrogram, Figure 5, describes different clusters for each drug 
formulation and it suggests an effective method to indentify the product or 
process of manufacture. This principle may be useful to identify different type of 
counterfeits including drugs that present the same composition, but different 
process of homogenization, particle size among other.  
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Figure 5. HCA of histograms for drugs A-F. 
 
In Figure 5, the images are identified 1 to 24 divided in 6 groups of 4 
replicates. The images of the same drug formulation have been clustered due 
the similarity of the profiles of histograms for each product. This pattern is 
repeated in all images analyzed. However, it is less evident for drugs C (Figure 
5 samples 9 to 12) and D (Figure 5 samples 13 to 16). Those drugs have the 
same specification and brand but different package characteristics.  
In this direction, the dendrogram obtained by HCA shows that this is an 
appropriate procedure for classification by multivariate similarity. However, 
more heterogeneous samples (flat histograms) are also less reproducible for 
the same image size. It is observed through the node of link of the clusters. In 
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contrast, images of the original product F (Figure 5 samples 21 to 24) showed a 
much better homogeneity and repeatability among images. 
 
Conclusions 
In this work, it was explored the technique of chemical mapping by near 
infrared spectroscopy in drug formulations with tablets of different sources in 
situations where the whole composition is not known. In such cases, it is very 
difficult to establish an appropriate calibration technique, so that only the 
information of sildenafil is considered independently of the excipients. The 
results obtained suggest an important way in which Multivariate Curve 
Resolution - Alternating Least Squares (MCR-ALS), by using the advantage of 
second order, can be successfully applied. Furthermore, the images of the 
active ingredient have been adequately explored by unsupervised classification 
of their histograms. In conclusion, the pattern recognition for homogeneity of 
images was possible. Thus, the presented methodology may be useful both for 
development of product and process, as well as, identification of the counterfeit. 
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